



## PRESS RELEASE

# roPROTix featured as a game changer in drug discovery

Frankfurt, July 2023

Perspixon's innovative AI-powered drug discovery platform roPROTix is featured in Nature's Biopharma DealMakers, the premier publication for information on dealmaking and industry trends in the biopharma space.

The article recognizes the potential of roPROTix to fundamentally change the way R&D is done by combining the three mega trends Multi-Specific Antibodies, Platform Technology, and AI- and ML-powered biological Drug Design.

Developed by Perspixon, roPROTix is a drug discovery platform for the rapid design and production of next-generation multi-specific antibodies. By connecting automated high-throughput experimentation with *in silico* data generation and AI-powered molecule design in a closed loop configuration, Perspixon will be able to decipher the design principles of next-generation multi-targeting drugs, and significantly reduce development time and costs.

Please see here for a full download of the article: <https://www.nature.com/articles/d43747-023-00025-z> which will also be featured in the September issues of Nature Biotechnology and Nature Reviews in Drug Discovery.

"We find it very reassuring to see how much recognition we get for our disruptive technology. There is no doubt that we will make best use of it to the benefit of patients and industry partners alike" says Matthias Wiedenfels, CEO of Perspixon Biotech.

"With its unprecedented data-generation capabilities, Perspixon will be at the forefront of AI-based innovation in the area of multi-specific antibody development", says Hartmut Michel, Nobel laureate and Perspixon scientific advisor.

\*\*\*

**For further media information/interview opportunities please contact:**

Dr. José Airas

T +49 (0)177 577 9828

E [info@perspixonbio.tech](mailto:info@perspixonbio.tech)

### Notes to editors:

*Perspixon is a biotech company specialized in multi-specific antibodies. Perspixon creates next-generation biotherapeutics through an end-to-end automated discovery platform. The company aims to radically accelerate the technical development of biological drug modalities with predictive AI, significantly reducing drug development times and costs. The roPROTix platform automatically generates tens of thousands of in-silico designed modalities and analyses them for key functional and biophysical properties in a parallelized approach. This digitally integrated process generates interrelated and multidimensional datasets of unprecedented quantity and quality, which feed directly into ML algorithms that drive the in-silico design engine.*

*Perspixon is headquartered in the FIZ Frankfurt Innovation Center for Biotechnology, Germany*